The interpretation of the scales is done in accordance with the EORTC-QLQ-C30 guidelines. The result shows a moderate clinically relevant difference with a difference of more than 10 points, 5-10 points indicates a small difference and fewer than 5 points no clinically relevant difference. To the third point, as we wrote in our introduction a stoma is shown to have a negative effect on body image and sexual function. Recently published data on female sexuality found sexual problems after treatment for colorectal cancer correlated with a permanent stoma and radiotherapy [1]. The current study only covers quality of life from the EORTC-QLQ-C30 questionnaire and an anchor question regarding the impact on QoL of bowel function/stoma. Finally, to the fourth point, in multivariate analysis LAR patients showed lower global health status, and higher occurrence of constipation and diarrhoea, when adjusted for gender and neoadjuvant therapy. In spite of a significantly larger proportion of APE patients receiving neoadjuvant radiotherapy, this did not affect QoL in these patients. In addition, 51 (10 %) of our LAR patients with tumours less than 10 cm from the anal verge were taken out of this analysis because they ended up with a permanent stoma. We certainly agree with our colleagues that our findings in this cross-sectional study should be interpreted with caution. We encourage colleagues to inform patients with low rectal cancers about life with a stoma and the risk of LAR syndrome in order to enable patients to make an informed decision.